SCHEMBL23551036

SCHEMBL23551036

CP(S)O[C@H]1CC[C@@H](C(=O)NC(CCC(=O)NC(CCC(=O)NCCOCCON)C(=O)NCCOCCON)C(=O)NCCOCCON)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.43
▸ POLB P06746 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ GRIN1 Q05586 2/20 0.31
▸ GRIN2A Q12879 2/20 0.31
▸ PLG P00747 2/20 0.31
▸ PRSS1 P07477 2/20 0.31
▸ PRSS2 P07478 2/20 0.31
▸ PRSS3 P35030 2/20 0.31
▸ PLAU P00749 1/20 0.31
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNB4 P30926 1/20 0.31
▸ CHRNA3 P32297 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31
▸ GRM1 Q13255 1/20 0.31
▸ CHRNA1 P02708 1/20 0.30
▸ CHRNG P07510 1/20 0.30
▸ CHRNB1 P11230 1/20 0.30
▸ CHRND Q07001 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24479396 0.85 GLP1R (0.42) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL20375331 0.85 GLP1R (0.42) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL21287423 0.85 GLP1R (0.42) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL20800932 0.84 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL18715404 0.84 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL24479569 0.84 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL18715377 0.84 GLP1R (0.43) GLP1RPOLBALDH1A1MAPTGRIN1
SCHEMBL26026996 0.83 GLP1R (0.46) GLP1RGRIN1GRIN2ACHRNB2CHRNB4
SCHEMBL23870009 0.83 GLP1R (0.43) GLP1RPOLBPLGPRSS1PRSS2
SCHEMBL24264573 0.83 GLP1R (0.43) GLP1RPOLBPLGPRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230272382-A1 COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES BANK OF AMERICA, N.A. 2023-08-31 — — US disclosed
US-20210189400-A1 PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF BANK OF AMERICA, N.A. 2021-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210189400-A1 PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF PNPLA2, PLAAT3, PNLIP GLP1R 752/4885POLB 1265/4885ALDH1A1 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback